



The 'Result of AGM' announcement released on 19/12/2022 at 12.01 under RNS No 1882K, did not include Resolutions 11 and 12. All Resolutions are now shown below and all other text remains the same.

Renalytix plc
("Renalytix" or the "Company")

Result of AGM

LONDON and SALT LAKE, 19 December 2022 – Renalytix (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled *in vitro* diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.

The results of the AGM are detailed below:

Resolution	In Favour		Against		Withheld
	Votes	%	Votes	%	
1	36,757,852	99.87%	48,952	0.13%	9,492
2	29,678,455	80.64%	7,125,845	19.36%	11,996
3	28,811,868	93.45%	2,019,388	6.55%	5,985,040
4	36,062,793	97.97%	747,409	2.03%	6,094
5	36,057,816	97.95%	753,695	2.05%	4,785
6	30,523,447	82.92%	6,285,397	17.08%	7,452
7	36,705,602	99.72%	102,842	0.28%	7,852
8	36,733,085	99.78%	79,463	0.22%	3,748
9	36,744,286	99.81%	69,330	0.19%	2,680
10	36,708,920	99.75%	92,058	0.25%	15,318
Special Resolutions					
11	31,542,960	85.70%	5,262,355	14.30%	10,981
12	36,217,902	99.81%	67,995	0.19%	530,399

For further information, please contact:

Renalytix plc

James McCullough, CEO

www.renalytix.com

Via Walbrook PR

Stifel (Nominated Adviser, Joint Broker)

Alex Price / Nicholas Moore

Tel: 020 7710 7600

Investec Bank plc (Joint Broker)

Gary Clarence / Daniel Adams

Tel: 020 7597 4000

Walbrook PR Limited

Tel: 020 7933 8780 or renalytix@walbrookpr.com

About KidneyIntelX™

KidneyIntelX™ is a laboratory developed test demonstrated to be a reliable, bioprognostic™ methodology that yields a simple-to-understand, custom risk score, enabling prediction of which adult patients with T2D and early CKD (stages 1-3) are at low, intermediate or high risk for rapid progressive decline in kidney function. By combining information from KidneyIntelX with newer cardio- and reno-protective therapies, doctors will have more information in determining which patients are at higher versus lower risk for rapid disease progression and may be able to more appropriately target resources and guideline-recommended treatments to advance kidney health. KidneyIntelX is supported by a growing body of clinical, utility and health economic studies (including a validation study of two large cohorts) and has demonstrated a 72% improvement in predicting those patients who are at high risk for rapid progressive decline in kidney function versus the current standard of care (eGFR and UACR). KidneyIntelX has received Breakthrough Device Designation from the U.S. Food and Drug Administration and Renalytix has submitted for De Novo marketing authorization. To learn more about KidneyIntelX and review the evidence, visit www.kidneyintelx.com.

About Renalytix

Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that enables early-stage chronic kidney disease progression risk assessment. The Company's lead product, KidneyIntelX™, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.